SCI Pharmtech
Market Cap
NT$7.4b
Last Updated
2021/01/23 08:49 UTC
Data Sources
Company Financials +
Executive Summary
SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and custom products worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with solid track record and pays a dividend.
Share Price & News
How has SCI Pharmtech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4119 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 4119's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
Market Performance
7 Day Return
-7.5%
4119
-2.4%
TW Pharmaceuticals
2.5%
TW Market
1 Year Return
-9.3%
4119
28.2%
TW Pharmaceuticals
31.6%
TW Market
Return vs Industry: 4119 underperformed the TW Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: 4119 underperformed the TW Market which returned 31.6% over the past year.
Shareholder returns
| 4119 | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.5% | -2.4% | 2.5% |
| 30 Day | 13.6% | -10.2% | 11.8% |
| 90 Day | -22.8% | -21.6% | 22.9% |
| 1 Year | -5.1%-9.3% | 30.4%28.2% | 36.3%31.6% |
| 3 Year | 74.6%55.5% | 34.3%27.1% | 59.7%41.8% |
| 5 Year | 57.8%26.4% | 6.4%-1.6% | 136.2%94.8% |
Long-Term Price Volatility Vs. Market
How volatile is SCI Pharmtech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates3 weeks ago | Simply Wall St
Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?1 month ago | Simply Wall St
Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?Valuation
Is SCI Pharmtech undervalued compared to its fair value and its price relative to the market?
10.15x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 4119 (NT$93) is trading above our estimate of fair value (NT$43.45)
Significantly Below Fair Value: 4119 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 4119 is good value based on its PE Ratio (10.1x) compared to the TW Pharmaceuticals industry average (17.3x).
PE vs Market: 4119 is good value based on its PE Ratio (10.1x) compared to the TW market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: 4119 is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: 4119's PB Ratio (2x) is in line with the TW Pharmaceuticals industry average.
Next Steps
Future Growth
How is SCI Pharmtech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
14.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4119's forecast earnings growth (14.8% per year) is above the savings rate (0.8%).
Earnings vs Market: 4119's earnings (14.8% per year) are forecast to grow slower than the TW market (18.6% per year).
High Growth Earnings: 4119's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4119's revenue is expected to decline over the next 3 years (-31.4% per year).
High Growth Revenue: 4119's revenue is forecast to decline over the next 3 years (-31.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4119's Return on Equity is forecast to be low in 3 years time (10.4%).
Next Steps
Past Performance
How has SCI Pharmtech performed over the past 5 years?
15.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4119 has high quality earnings.
Growing Profit Margin: 4119's current net profit margins (26.9%) are higher than last year (25.7%).
Past Earnings Growth Analysis
Earnings Trend: 4119's earnings have grown by 15.4% per year over the past 5 years.
Accelerating Growth: 4119's earnings growth over the past year (23.1%) exceeds its 5-year average (15.4% per year).
Earnings vs Industry: 4119 earnings growth over the past year (23.1%) underperformed the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 4119's Return on Equity (20.1%) is considered high.
Next Steps
Financial Health
How is SCI Pharmtech's financial position?
Financial Position Analysis
Short Term Liabilities: 4119's short term assets (NT$1.4B) exceed its short term liabilities (NT$595.2M).
Long Term Liabilities: 4119's short term assets (NT$1.4B) exceed its long term liabilities (NT$22.3M).
Debt to Equity History and Analysis
Debt Level: 4119 is debt free.
Reducing Debt: 4119 had no debt 5 years ago.
Debt Coverage: 4119 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4119 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is SCI Pharmtech current dividend yield, its reliability and sustainability?
6.24%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4119's dividend (6.24%) is higher than the bottom 25% of dividend payers in the TW market (2.1%).
High Dividend: 4119's dividend (6.24%) is in the top 25% of dividend payers in the TW market (5.16%)
Stability and Growth of Payments
Stable Dividend: 4119 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 4119's dividend payments have increased, but the company has only paid a dividend for 6 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (63.3%), 4119's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 4119's dividends in 3 years are forecast to be covered by earnings (50.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Yon-Lian Wu
no data
Tenure
Dr. Yon-Lian Wu serves as the Chief Executive Officer of SCI Pharmtech, Inc.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Top Shareholders
Company Information
SCI Pharmtech, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: SCI Pharmtech, Inc.
- Ticker: 4119
- Exchange: TSEC
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$7.392b
- Shares outstanding: 79.49m
- Website: https://www.sci-pharmtech.com.tw
Number of Employees
Location
- SCI Pharmtech, Inc.
- No. 61, Haihu North Road
- Lane 309
- Taoyuan City
- 33856
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4119 | TSEC (Taiwan Stock Exchange) | Yes | Common Stock | TW | TWD | Jan 2004 |
Biography
SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and custom products worldwide. Its active pharmaceutical ingredients include allopurinol, amobarbital, pr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 08:49 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.